In this video and post, I discuss some common myths and misconceptions about CBD. This video was inspired by a paper by Dr. Ethan Russo, which I link to below.
Some misconceptions about CBD:
1. CBD is not psychoactive.
While CBD is not intoxicating, to say it is non-psychoactive is a bit of a mischaracterization of CBD. CBD can have an effect on the user’s mental state. This is why CBD has been found to be so useful for anxiety, depression, and mental illness. It is more accurate to say that CBD is non-intoxicating instead of non-psychoactive.
2. CBD is sedating.
While some people might find CBD to be sedating, for others, even in high doses, CBD has shown to be alerting or not sedating. The sedating effect of some CBD products can be attributed to sedating terpenes like myrcene contained in products which are full plant extracts.
3. CBD is a CB1 inverse agonist like Rimonabant.
Rimonabant is a synthetic cannabinoid inverse agonist which was used to treat obesity and metabolic syndrome in Europe. Rimonabant was quickly removed from the market because of serious side effects including anxiety, suicidal ideation, and nausea. CBD on the other hand, does not act as an inverse agonist on the CB1 receptor and thus does not cause the same nasty side effects as Rimonabant. Rather, CBD works as an antagonist at the CB1 receptor. This is partially how CBD can dampen some of the unwanted effects of THC.
Check out: How does CBD work?
4. CBD is legal in all 50 states.
The legal status of CBD still remains a gray issue. While most lawyers working in the cannabis space will say CBD from hemp is legal so long as it is sourced from a compliant Farm Bill state, clarity still needs to be established on the legal status of CBD. This is especially true on the federal level.
5. CBD turns into THC in the body.
This misconception came from a study which showed that this conversion was possible under certain experimental circumstances. However there is no evidence that this conversion happens in the human body when a person takes CBD.
Cannabidiol Claims and Misconceptions: (Trends in Pharmacological Sciences 38, 198-201, 2017)